| Literature DB >> 31336570 |
Mauro Vaisberg1, Vitoria Paixão1, Ewin B Almeida1, Juliana M B Santos1, Roberta Foster1, Marcelo Rossi1, Tania C Pithon-Curi2, Renata Gorjão2, Cesar M Momesso2, Marília S Andrade3, José R Araujo4, Maurício C Garcia5, Moises Cohen5, Elisabeth C Perez6, Alana Santos-Dias7, Rodolfo P Vieira8,9,10,11, André L L Bachi12,13.
Abstract
BACKGROUND: Although Lactobacillus casei Shirota (LcS) can benefit the immune status, the effects of LcS in the immune/inflammatory responses of marathon runners has never been evaluated. Therefore, here we evaluated the effect of daily ingestion of fermented milk containing or not LcS in the systemic and upper airway immune/inflammatory responses before and after a marathon.Entities:
Keywords: antimicrobial peptides; cytokines; neutrophil infiltration; probiotics; secretory immunoglobulin A
Year: 2019 PMID: 31336570 PMCID: PMC6682935 DOI: 10.3390/nu11071678
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flow diagram of the study.
Figure 2Experimental design.
Physical characteristics (age, weight, height, total body fat, total muscle mass and body mass index (BMI)), and aerobic capacity (relative VO2max) of the volunteers allocated in the groups LcS and placebo. All data were analyzed using Student’s t-test and are presented in mean and standard deviation. The level of significance was 5% (p < 0.05).
| Variables | Volunteers ( | |
|---|---|---|
| Placebo ( | LcS ( | |
| Age (year) | 40.1 ± 10.3 | 39.6 ± 8.8 |
| Weight (kg) | 76.5 ± 10.4 | 72.4 ± 7.8 |
| Height (cm) | 176.9 ± 7.6 | 173.8 ± 6.4 |
| Total body fat (%) | 18.6 ± 7.5 | 16.5 ± 6.6 |
| Total muscle mass (g) | 58.1 ± 4.7 | 54.7 ± 5.9 |
| BMI (kg/m2) | 24.4 ± 2.2 | 23.4 ± 2.4 |
| Relative VO2max (ml/kg/min) | 57.64 ± 6.89 | 57.86 ± 6.85 |
| Time of conclusion of the race (hours) | 04:09:20 ± 00:19:56 | 04:15:30 ± 00:15:22 |
Figure 3LcS maintain salivary immune protection after the marathon. Salivary concentration of secretory immunoglobulin A (SIgA, g/mL, (A) and the antimicrobial peptides defensing-1 (ng/mL (B), lysozyme (ng/mL (C), cathelicidin LL-37 (ng/mL (D), and lactoferrin (g/mL (E) in the volunteers of the placebo and LcS groups at five different occasions: before (Pre) and 30 days after the ingestion of the fermented milk containing or not containing LcS (Post-ingestion); immediately (IM); 72 hours (72 h) and 14 days (14 d) after the marathon ends. Values are presented in the median with the respective quartiles. The risk value was set at 5% (p < 0.05). * p < 0.05 and ** p < 0.01.
Percentage of neutrophil infiltration on nasal mucosa of the study volunteers separated into groups LcS and placebo. All data are presented in mean and standard deviation and were analyzed by Student’s t-test. The level of significance was 5% (p < 0.05).
| Variable | Volunteers ( | |||||
|---|---|---|---|---|---|---|
| Placebo ( | ||||||
| Pre | Post | IM | 72 h | 14 d | ||
| Neutrophil (%) | 50 ± 3 | 43 ± 6 * | 38 ± 3 *,# | 53 ± 4 * | 56 ± 3 | <0.05 |
| LcS ( | ||||||
| 45 ± 4 ø | 21 ± 3 | 28 ± 2 | 29 ± 3 | 48 ± 6 ø | <0.05 | |
* differences between placebo and LcS group for the same occasion; # differences between IM and Pre, 72 h and 14 d in placebo group; ø differences between Pre or 14 d and Post, and IM and 72 h in LcS group.
Figure 4LcS increase anti-inflammatory response on the upper airways after the marathon. Concentration (pg/mg of total protein) of IL-1β (A), IL-1ra (B), IL-4 (C), IL-5 (D), IL-6 (E), IL-10 (F), IL-12p70 (G), IL-13 (H), and TNF- (I) in nasal mucosal lavage of the volunteers in the placebo and LcS groups at five different occasions: before (Pre) and 30 days after the ingestion of the fermented milk containing or not containing LcS (Post-ingestion); immediately (IM); 72 hours (72 h) and 14 days (14 d) after the marathon ends. Values are presented in median with the respective quartiles. * p < 0.05; ** p < 0.01 and *** p < 0.001.
Figure 5LcS increase systemic IL-12p70 levels after the marathon Serum concentration (pg/mL) of IL-1β (A), IL-1ra (B), IL-4 (C), IL-5 (D), IL-6 (E), IL-10 (F), IL-12p70 (G), IL-13 (H), and TNF- (I) in the placebo and LcS groups at five different occasions: before (Pre) and 30 days after the ingestion of the fermented milk containing or not containing LcS (Post-ingestion); immediately (IM); 72 hours (72 h) and 14 days (14 d) after the marathon. Values are presented in median with the respective quartiles. * p < 0.05; ** p < 0.01 and *** p < 0.001.
Ratio of IL-10 and IL-12p70 (IL-10/IL-12p70) in the serum and nasal mucosa lavage of the study volunteers separated into groups LcS and placebo obtained in five different occasions (Pre, Post, IM. 72 h e 14 d). All data are presented in mean and standard deviation and were analyzed by a nonparametric n-sample signed rank test (Quade test) with a post hoc Quade testing was conducted with pairwise case analysis. The level of significance was 5% (p < 0.05).
| Variable/Occasion | IL-10/IL-12p70 ratio | |||||
|---|---|---|---|---|---|---|
| Group/Sample | Pre | Post | IM | 72 h | 14 d | |
| Placebo/Serum | 1.05 ± 0.10 | 1.12 ± 0.16 | 1.63 ± 0.43 | 1.28 ± 0.19 | 1.16 ± 0.11 | |
| LcS/Serum | 1.09 ± 0.11 | 1.07 ± 0.13 | 1.40 ± 0.15 | 1.30 ± 0.13 | 1.11 ± 0.09 | |
| Placebo/Nasal mucosa lavage | 1.20 ± 0.47 | 0.83 ± 0.10 | 1.12 ± 0.13 | 0.84 ± 0.11 | 1.00 ± 0.11 | |
| LcS/Nasal mucosa lavage | 0.81 ± 0.10 | 0.94 ± 0.13 | 5.84 ± 2.74 *,# | 0.95 ± 0.12 | 0.76 ± 0.10 | |
* differences between placebo and LcS group for the same occasion (p < 0.001); # differences between IM (immediately post-marathon) and the other occasions in the LcS group (p < 0.001).